It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Replication errors and various genotoxins cause DNA double-strand breaks (DSBs) where error-prone repair creates genomic mutations, most frequently focal deletions, and defective repair may lead to neurodegeneration. Despite its pathophysiological importance, the extent to which faulty DSB repair alters the genome, and the mechanisms by which mutations arise, have not been systematically examined reflecting ineffective methods. Here, we develop PhaseDel, a computational method to detect focal deletions and characterize underlying mechanisms in single-cell whole genome sequences (scWGS). We analyzed high-coverage scWGS of 107 single neurons from 18 neurotypical individuals of various ages, and found that somatic deletions increased with age and in highly expressed genes in human brain. Our analysis of 50 single neurons from DNA repair-deficient diseases with progressive neurodegeneration (Cockayne syndrome, Xeroderma pigmentosum, and Ataxia telangiectasia) reveals elevated somatic deletions compared to age-matched controls. Distinctive mechanistic signatures and transcriptional associations suggest roles for somatic deletions in neurodegeneration.
DNA damage has been implicated in aging and neurodegeneration. Here, the authors develop a bioinformatic method to detect deletions in single neuron genome sequences and reveal an increased burden of somatic deletions during aging and in DNA repair disorders.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 Boston Children’s Hospital, Division of Genetics and Genomics, Boston, USA (GRID:grid.2515.3) (ISNI:0000 0004 0378 8438); Boston Children’s Hospital, Manton Center for Orphan Disease, Boston, USA (GRID:grid.2515.3) (ISNI:0000 0004 0378 8438); Harvard Medical School, Department of Pediatrics, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Broad Institute of MIT and Harvard, Cambridge, USA (GRID:grid.66859.34) (ISNI:0000 0004 0546 1623); Sungkyunkwan University, Department of Biological Sciences, Suwon, South Korea (GRID:grid.264381.a) (ISNI:0000 0001 2181 989X)
2 Boston Children’s Hospital, Division of Genetics and Genomics, Boston, USA (GRID:grid.2515.3) (ISNI:0000 0004 0378 8438); Boston Children’s Hospital, Manton Center for Orphan Disease, Boston, USA (GRID:grid.2515.3) (ISNI:0000 0004 0378 8438); Harvard Medical School, Department of Pediatrics, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Broad Institute of MIT and Harvard, Cambridge, USA (GRID:grid.66859.34) (ISNI:0000 0004 0546 1623)
3 University of Massachusetts Medical School, Department of Molecular, Cell and Cancer Biology, Worcester, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364)
4 Boston Children’s Hospital, Division of Genetics and Genomics, Boston, USA (GRID:grid.2515.3) (ISNI:0000 0004 0378 8438); Boston Children’s Hospital, Manton Center for Orphan Disease, Boston, USA (GRID:grid.2515.3) (ISNI:0000 0004 0378 8438); Harvard Medical School, Department of Pediatrics, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Broad Institute of MIT and Harvard, Cambridge, USA (GRID:grid.66859.34) (ISNI:0000 0004 0546 1623); Boston Children’s Hospital, Howard Hughes Medical Institute, Boston, USA (GRID:grid.2515.3) (ISNI:0000 0004 0378 8438); Harvard Medical School, Department of Neurology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
5 Boston Children’s Hospital, Division of Genetics and Genomics, Boston, USA (GRID:grid.2515.3) (ISNI:0000 0004 0378 8438); Boston Children’s Hospital, Manton Center for Orphan Disease, Boston, USA (GRID:grid.2515.3) (ISNI:0000 0004 0378 8438); Harvard Medical School, Department of Pediatrics, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Broad Institute of MIT and Harvard, Cambridge, USA (GRID:grid.66859.34) (ISNI:0000 0004 0546 1623); Boston Children’s Hospital, Howard Hughes Medical Institute, Boston, USA (GRID:grid.2515.3) (ISNI:0000 0004 0378 8438); Harvard Medical School, Department of Neurology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Harvard Medical School, Department of Pathology, Brigham and Women’s Hospital, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)
6 Boston Children’s Hospital, Division of Genetics and Genomics, Boston, USA (GRID:grid.2515.3) (ISNI:0000 0004 0378 8438); Boston Children’s Hospital, Manton Center for Orphan Disease, Boston, USA (GRID:grid.2515.3) (ISNI:0000 0004 0378 8438); Harvard Medical School, Department of Pediatrics, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Broad Institute of MIT and Harvard, Cambridge, USA (GRID:grid.66859.34) (ISNI:0000 0004 0546 1623); University of Massachusetts Medical School, Department of Molecular, Cell and Cancer Biology, Worcester, USA (GRID:grid.168645.8) (ISNI:0000 0001 0742 0364); Boston Children’s Hospital, Howard Hughes Medical Institute, Boston, USA (GRID:grid.2515.3) (ISNI:0000 0004 0378 8438); Harvard Medical School, Department of Neurology, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)